Abstract
Transitional cell carcinomas of the urinary bladder are frequently characterised by multiple local recurrences with a low risk of progression. The observation that a significant proportion of patients experience recurrences over many years, even decades, without ever developing aggressive life threatening disease has led to the hypothesis that recurrence is a separate clinical and molecular event in the natural history of this disease. Over recent years a number of studies have been undertaken to test this hypothesis and within the last 12-24 months candidate loci and genes have been identified which may represent such recurrence related molecular events. Within this review we have summarised the data which identifies three key loci on chromosome 9q34, 11q23 and 17q25 as associated with recurrence and sought to place these findings in the context of a multistage molecular model of bladder cancer initiation, recurrence, progression and metastasis.
Keywords: bladder cancer, recurrence, progression, molecular genetics, review
Current Genomics
Title: Recurrence in Bladder Cancer: A Molecular Dead End?
Volume: 4 Issue: 5
Author(s): John M. S. Bartlett, Joanne Edwards and Ken M. Grigor
Affiliation:
Keywords: bladder cancer, recurrence, progression, molecular genetics, review
Abstract: Transitional cell carcinomas of the urinary bladder are frequently characterised by multiple local recurrences with a low risk of progression. The observation that a significant proportion of patients experience recurrences over many years, even decades, without ever developing aggressive life threatening disease has led to the hypothesis that recurrence is a separate clinical and molecular event in the natural history of this disease. Over recent years a number of studies have been undertaken to test this hypothesis and within the last 12-24 months candidate loci and genes have been identified which may represent such recurrence related molecular events. Within this review we have summarised the data which identifies three key loci on chromosome 9q34, 11q23 and 17q25 as associated with recurrence and sought to place these findings in the context of a multistage molecular model of bladder cancer initiation, recurrence, progression and metastasis.
Export Options
About this article
Cite this article as:
Bartlett M. S. John, Edwards Joanne and Grigor M. Ken, Recurrence in Bladder Cancer: A Molecular Dead End?, Current Genomics 2003; 4 (5) . https://dx.doi.org/10.2174/1389202033490295
DOI https://dx.doi.org/10.2174/1389202033490295 |
Print ISSN 1389-2029 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5488 |
Call for Papers in Thematic Issues
Advanced AI Techniques in Big Genomic Data Analysis
The thematic issue on "Advanced AI Techniques in Big Genomic Data Analysis" aims to explore the cutting-edge methodologies and applications of artificial intelligence (AI) in the realm of genomic research, where vast amounts of data pose both challenges and opportunities. This issue will cover a broad spectrum of AI-driven strategies, ...read more
Advanced Computational Algorithms and Artificial Intelligence in Clinical Pharmacogenomics
In the era of personalized medicine, understanding the relationship between genetics and drug response is crucial. This issue delves into innovative methodologies, leveraging deep computational analysis and artificial intelligence, to enhance the field of Clinical Pharmacogenomics. The interdisciplinary approach harnesses the power of advanced high-throughput genotyping technologies, sophisticated computational analysis, ...read more
Applications of Single-cell Sequencing Technology in Reproductive Medicine
Single cell sequencing (SCS) technology utilizes individual cells' genetic material to sequence their genome, transcriptome, and epigenetics at the molecular level. It offers insights into cell heterogeneity and enables the study of limited biological materials. Since its recognition as a valuable technique in 2011, single cell sequencing has yielded numerous ...read more
Big Data in Cancer Research
Cancer is a significant threat to human life and health, remaining a highly aggressive killer. It is a leading cause of death worldwide and represents a crucial medical issue for humanity. However, in the past decade, the effectiveness of new synthetic anticancer agents has not matched the current clinical speculation. ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Osteoporotic Fracture Healing: Potential Use of Medicinal Plants from the Tropics
Current Drug Targets Zebrafish Model in Drug Safety Assessment
Current Pharmaceutical Design CDK Inhibitors: From the Bench to Clinical Trials
Current Drug Targets Can PET Imaging Facilitate Optimization of Cancer Therapies?
Current Pharmaceutical Design Drug Delivery Nanoparticles in Treating Chemoresistant Tumor Cells
Current Medicinal Chemistry Analytical Methods for Metallothionein Detection
Current Analytical Chemistry Self-immolative Linkers in Prodrugs and Antibody Drug Conjugates in Cancer Treatment
Recent Patents on Anti-Cancer Drug Discovery Recent Advances on Radionuclide Labeled Hypoxia-Imaging Agents
Current Pharmaceutical Design Recent Advances and Challenges in Steroid Metabolomics for Biomarker Discovery
Current Medicinal Chemistry The Influence of Host Factors on the Prognosis of Breast Cancer: Stroma and Immune Cell Components as Cancer Biomarkers
Current Cancer Drug Targets Flavonoids as Anticancer Agents: Recent Progress and State of the Art?
Current Organic Chemistry Vascular Endothelial Growth Factor (VEGF) as a Target of Bevacizumab in Cancer: From the Biology to the Clinic
Current Medicinal Chemistry Cytokines and Chemokines as Regulators of Angiogenesis in Health and Disease
Current Pharmaceutical Design Bacterial Zinc Proteases and their Inhibition
Current Enzyme Inhibition Bisphosphonate Anticancer Activity in Prostate Cancer and Other Genitourinary Cancers
Anti-Cancer Agents in Medicinal Chemistry Investigation of in Vitro Release Dynamics of Cisplatin from Genipin Crosslinked Gelatin Nanocarriers
Drug Delivery Letters The Role of Hypoxia in Endometrial Cancer
Current Pharmaceutical Biotechnology XMT-1001, A Novel Biodegradable Polyacetal Polymer Conjugate of Camptothecin in Clinical Development
Current Bioactive Compounds Insulin Management for Type 1 Diabetic Patients During Social Alcohol Consumption: The SPRITZ Study
Current Diabetes Reviews The Application of lncRNAs in Cancer Treatment and Diagnosis
Recent Patents on Anti-Cancer Drug Discovery